110 related articles for article (PubMed ID: 11176534)
1. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence.
Myers RB; Oelschlager DK; Weiss HL; Frost AR; Grizzle WE
J Urol; 2001 Mar; 165(3):1027-32. PubMed ID: 11176534
[TBL] [Abstract][Full Text] [Related]
2. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager DK; Coan PN; Frost AR; Weiss HL; Manne U; Pretlow TG; Grizzle WE
J Urol; 1999 Mar; 161(3):945-9. PubMed ID: 10022731
[TBL] [Abstract][Full Text] [Related]
3. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state.
Oka H; Chatani Y; Kohno M; Kawakita M; Ogawa O
Int J Urol; 2005 Oct; 12(10):899-905. PubMed ID: 16323984
[TBL] [Abstract][Full Text] [Related]
6. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis levels increase after castration in the CWR22 human prostate cancer xenograft.
Smitherman AB; Gregory CW; Mohler JL
Prostate; 2003 Sep; 57(1):24-31. PubMed ID: 12886520
[TBL] [Abstract][Full Text] [Related]
8. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer.
Mohler JL; Morris TL; Ford OH; Alvey RF; Sakamoto C; Gregory CW
Prostate; 2002 Jun; 51(4):247-55. PubMed ID: 11987153
[TBL] [Abstract][Full Text] [Related]
9. Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
Pollack A; Block NL; Stover BJ; Irvin GL
Cancer Res; 1985 Mar; 45(3):1052-7. PubMed ID: 3971360
[TBL] [Abstract][Full Text] [Related]
10. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
Glasscock LN; Réhault SM; Gregory CW; Cooper ST; Jackson TP; Hoffman M; Church FC
Exp Mol Pathol; 2005 Aug; 79(1):23-32. PubMed ID: 15878512
[TBL] [Abstract][Full Text] [Related]
11. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.
Fizazi K; Martinez LA; Sikes CR; Johnston DA; Stephens LC; McDonnell TJ; Logothetis CJ; Trapman J; Pisters LL; Ordoñez NG; Troncoso P; Navone NM
Clin Cancer Res; 2002 Mar; 8(3):775-81. PubMed ID: 11895908
[TBL] [Abstract][Full Text] [Related]
12. Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma.
Myers RB; Oelschlager D; Manne U; Coan PN; Weiss H; Grizzle WE
Int J Cancer; 1999 Jul; 82(3):424-9. PubMed ID: 10399960
[TBL] [Abstract][Full Text] [Related]
13. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
14. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy.
Tang Y; Wang L; Goloubeva O; Khan MA; Zhang B; Hussain A
Clin Cancer Res; 2008 May; 14(10):2936-43. PubMed ID: 18483360
[TBL] [Abstract][Full Text] [Related]
15. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
16. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
17. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Rossi S; Graner E; Febbo P; Weinstein L; Bhattacharya N; Onody T; Bubley G; Balk S; Loda M
Mol Cancer Res; 2003 Aug; 1(10):707-15. PubMed ID: 12939396
[TBL] [Abstract][Full Text] [Related]
19. [Androgens and increased lipogenesis in prostate cancer. Cell biologic and clinical perspectives].
Verhoeven G
Verh K Acad Geneeskd Belg; 2002; 64(3):189-95; discussion 195-6. PubMed ID: 12238242
[TBL] [Abstract][Full Text] [Related]
20. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Krenning EP; de Jong M
J Nucl Med; 2007 Jan; 48(1):88-93. PubMed ID: 17204703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
